{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:42:04Z","timestamp":1792442524587,"version":"4.5.0"},"reference-count":8,"publisher":"American Society of Consultant Pharmacists","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["sr care pharm"],"published-print":{"date-parts":[[2026,8,1]]},"DOI":"10.4140\/tcp.n.2026.157","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:34:19Z","timestamp":1786350859000},"page":"157-158","source":"Crossref","is-referenced-by-count":0,"title":["Comment on \u201cReview of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer\u2019s Disease: Progress and Challenges\u201d"],"prefix":"10.4140","volume":"41","author":[{"given":"Marketa","family":"Marvanova","sequence":"first","affiliation":[{"name":"Dean and Professor, Pacific University School of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2625","reference":[{"key":"ref1","year":"2025"},{"key":"ref2","year":"2025","journal-title":"Eli Lilly and Company."},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"e70062","DOI":"10.1002\/alz.70062","article-title":"Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction.","volume":"21","year":"2025","journal-title":"Alzheimer\u2019s Dement"},{"key":"ref4","article-title":"FDA approves LEQEMBITM (lecanemab-irmb) IV maintenance dosing for the treatment of early Alzheimer\u2019s disease.","year":"2025","journal-title":"News release."},{"key":"ref5","article-title":"Risk of amyloid-related imaging abnormalities and intracerebral hemorrhage with anticoagulant use in patients receiving anti-amyloid therapies for Alzheimer\u2019s disease: a systematic review and meta-analysis.","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 7","key":"ref6","first-page":"e108905","article-title":"The lecanemab Clarity AD open-label extension in early Alzheimer\u2019s disease: Initial findings from the 48-month analysis.","volume":"21","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"e70905","DOI":"10.1002\/alz.70905","article-title":"Long-term safety and efficacy of lecanemab in early Alzheimer\u2019s disease: Results from the CDlarity AD open-label extension study.","volume":"21","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"100446","DOI":"10.1016\/j.tjpad.2025.100446","article-title":"Donanemab in early symptomatic Alzheimer\u2019s disease: results from the TRAILBLAZER-ALZ 2 long-term extension.","volume":"13","year":"2026","journal-title":"J Prev Alzheimers Dis"}],"container-title":["The Senior Care Pharmacist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ascp\/tscp\/2026\/00000041\/00000005\/art00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:30:32Z","timestamp":1792441832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.4140\/TCP.n.2026.157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8,1]]}},"alternative-id":["2639-9636(20260801)41:5L.157;1-"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2026.157","relation":{},"ISSN":["2639-9636"],"issn-type":[{"value":"2639-9636","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}